Companies /Healthcare

Twist Bioscience Corp

NASDAQ: TWST Biotechnology
$116.35
▲ $4.35 (+3.88%) today
Markets closed · 12:53am ET

TWST at a Glance

Valuation
Market cap
$7.4B
Profitability
Revenue (TTM)
$459.4M
Profit margin
-28.3%
EPS (TTM)
$-2.23
Price
52-week range
$26 – $220
Street target
$128.92
Earnings
Next report
Feb 1, 2027

Headquartered in South San Francisco, CA Fiscal year ends September NASDAQ: TWST twistbioscience.com

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology and genomics tools company. It uses a silicon-based DNA synthesis platform to make customized molecules at scale for diagnostics, therapeutics, industrial, agriculture and research customers.

The company reports two segments:
- DNA Synthesis and Protein Solutions: synthetic genes, oligos, DNA libraries, protein production, antibody discovery and characterization services.
- NGS Applications: next-generation sequencing workflow tools, such as target enrichment panels, including custom minimal residual disease (MRD) panels.

In fiscal 2026 Twist shipped products to about 4,100 customers and physically shipped about 1.3 million genes. It is increasingly serving AI-enabled drug discovery customers; its fiscal 2027 outlook assumes [USD:100000000] in AI drug discovery revenue. Recent offerings include Twist Express Screening Antibodies and Twist MRD Express. The company also provides antibody characterization services through Lilly TuneLab. Updated

Latest Activity

TWSTTwist Bioscience
Q4 2026
EPS
-$0.32
est -$0.20-57.6%
Revenue
$127M
est $124M+2.5%

Fiscal 2027 guidance of $550 million to $560 million leans on $100 million from AI drug discovery customers, a concentration bet investors are repricing right now. Revenue topped estimates and adjusted EBITDA turned positive at $2.2 million, but the wider loss per share missed expectations as SG&A climbed to $74.7 million.

Quarterly EPS — reported vs estimate

TWST Coverage

11:53am ET
Investing

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

Cathie Wood’s Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary…

Joey Frenette
9:29am ET
Investing

1 Top Technology ETF to Buy and 1 to Avoid

The technology-oriented Nasdaq 100 index is back into correction territory, down 10.5% after hitting an all-time high last month. The tech sector has been the driving force for the stock market’s gains…

Rich Duprey

Frequently Asked Questions

What does Twist Bioscience do?

Twist Bioscience Corporation is a synthetic biology and genomics tools company. It uses a silicon-based DNA synthesis platform to make customized molecules at scale for diagnostics, therapeutics, industrial, agriculture and research customers.

What is the TWST stock price target?

The Wall Street consensus 12-month price target for TWST is $128.92.